TouchNEUROLOGY Editorial Board member Jeffrey Cummings explores the use of lecanemab (BAN2401) for the treatment of early Alzheimer's disease

28/01/2022

During 2021, Eisai and Biogen announced that the US Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for lecanemab (also known as BAN2401), an investigational antibody targeting amyloid beta, for the treatment of Alzheimer's disease (AD). In November, new data on lecanemab were presented at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference. touchNEUROLOGY Editorial Board member Jeffrey Cummings has published an article examining the trial results and discussing the use of lecanemab for early AD. You can read the article, here:

https://touchneurology.com/alzheimers-disease-dementia/journal-articles/innovative-therapeutic-development-programme-for-the-treatment-of-early-alzheimers-disease-lecanemab-ban2401/